Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea. The Dow ...

James Van Der Beek has been candid about his health ups and downs since announcing he was diagnosed with colorectal cancer in ...

Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM ...

Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share ...